In terms of sheer relevance, it's difficult to think of a more relevant sector than healthcare — and within this vast ecosystem, only an elite few occupy the same neighborhood as pharmaceutical giant Eli Lilly and Company (NYSE:LLY). In November 2025, Eli Lilly became the first trillion-dollar pharmaceutical company, mostly due to regulatory momentum for its blockbuster drugs.
Specifically, the pharma received approval by the Food and Drug Administration for Mounjaro (tirzepatide) as an adjunct to diet and exercise for type 2 diabetes. Thanks to a blistering rally between late October to nearly the end of last month, LLY stock decisively broke through the four-digit price point, thus triggering a market capitalization above $1 trillion.
